The RANKL/OPG system and bone mineral density in patients with chronic liver disease

Journal of Hepatology

Volumn 43, Issue 6, 2005, Pages 973-983

  Moschen, Alexander R ^a   Kaser, Arthur ^a   Stadlmann, Sylvia ^a   Millonig, Gunda ^a   Kaser, Susanne ^a   Mühllechner, Petra ^a   Habior, Andrzej ^b   Graziadei, Ivo ^a   Vogel, Wolfgang ^a   Tilg, Herbert ^a,c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

BMD; Bone mineral density; Chronic liver disease; OPG; Osteoprotegerin; RANKL

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; ARTICLE; BONE DENSITY; CHRONIC LIVER DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; GENDER; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DISEASES, METABOLIC; CARRIER PROTEINS; CHRONIC DISEASE; FEMALE; GLYCOPROTEINS; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 27744485576     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2005.05.034     Document Type: Article

References (46)

1. A.M. Diehl Cytokine regulation of liver injury and repair Immunol Rev 174 2000 160 171
2. H. Tilg, A. Wilmer, W. Vogel, M. Herold, B. Nolchen, and G. Judmaier Serum levels of cytokines in chronic liver diseases Gastroenterology 103 1992 264 274
3. Y. Sakao, K. Takeda, H. Tsutsui, T. Kaisho, F. Nomura, and H. Okamura IL-18-deficient mice are resistant to endotoxin-induced liver injury but highly susceptible to endotoxin shock Int Immunol 11 1999 471 480
4. H. Tilg, and A.M. Diehl Cytokines in alcoholic and nonalcoholic steatohepatitis N Engl J Med 343 2000 1467 1476
5. W.D. Leslie, C.N. Bernstein, and M.S. Leboff AGA technical review on osteoporosis in hepatic disorders Gastroenterology 125 2003 941 966
6. J.L. Gonzalez-Calvin, F. Gallego-Rojo, R. Fernandez-Perez, F. Casado-Caballero, E. Ruiz-Escolano, and E.G. Olivares Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis J Clin Endocrinol Metab 89 2004 4325 4330
7. P. Aukrust, N.B. Liabakk, F. Muller, E. Lien, T. Espevik, and S.S. Froland Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection - correlations to clinical, immunologic, and virologic parameters J Infect Dis 169 1994 420 424
8. A. Diez-Ruiz, G.P. Tilz, F. Gutierrez-Gea, B. Gil-Extremera, C. Murr, and H. Wachter Neopterin and soluble tumor necrosis factor receptor type I in alcohol-induced cirrhosis Hepatology 21 1995 976 978
9. S. Kakumu, A. Okumura, T. Ishikawa, M. Yano, A. Enomoto, and H. Nishimura Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease Clin Exp Immunol 109 1997 458 463
10. J. Dai, D. Lin, J. Zhang, P. Habib, P. Smith, and J. Murtha Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice J Clin Invest 106 2000 887 895
11. D.L. Lacey, E. Timms, H.L. Tan, M.J. Kelley, C.R. Dunstan, and T. Burgess Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 1998 165 176
12. W.S. Simonet, D.L. Lacey, C.R. Dunstan, M. Kelley, M.S. Chang, and R. Luthy Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 1997 309 319
13. L.C. Hofbauer, and A.E. Heufelder Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology J Mol Med 79 2001 243 253
14. L. Lum, B.R. Wong, R. Josien, J.D. Becherer, H. Erdjument-Bromage, and J. Schlondorff Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival J Biol Chem 274 1999 13613 13618
15. Y.Y. Kong, U. Feige, I. Sarosi, B. Bolon, A. Tafuri, and S. Morony Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand Nature 402 1999 304 309
16. A.J. Ashcroft, S.M. Cruickshank, P.I. Croucher, M.J. Perry, S. Rollinson, and J.M. Lippitt Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin Immunity 19 2003 849 861
17. D.M. Anderson, E. Maraskovsky, W.L. Billingsley, W.C. Dougall, M.E. Tometsko, and E.R. Roux A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function Nature 390 1997 175 179
18. V. Breuil, H. Schmid-Antomarchi, A. Schmid-Alliana, R. Rezzonico, L. Euller-Ziegler, and B. Rossi The receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) is a new chemotactic factor for human monocytes Fed Am Soc Exp Biol J 17 2003 1751 1753
19. D. Seshasayee, H. Wang, W.P. Lee, P. Gribling, J. Ross, and N. Van Bruggen A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response J Biol Chem 279 2004 30202 30209
20. J.G. Emery, P. McDonnell, M.B. Burke, K.C. Deen, S. Lyn, and C. Silverman Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL J Biol Chem 273 1998 14363 14367
21. H. Yasuda, N. Shima, N. Nakagawa, S.I. Mochizuki, K. Yano, and N. Fujise Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro Endocrinology 139 1998 1329 1337
22. V. Kartsogiannis, H. Zhou, N.J. Horwood, R.J. Thomas, D.K. Hards, and J.M. Quinn Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues Bone 25 1999 525 534
23. G. Hawa, N. Brinskelle-Schmal, K. Glatz, S. Maitzen, and W. Woloszczuk Immunoassay for soluble RANKL (receptor activator of NF-kappaB ligand) in serum Clin Lab 49 2003 461 463
24. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843: 1-129.
25. F. Szalay, D. Hegedus, P.L. Lakatos, I. Tornai, E. Bajnok, and K. Dunkel High serum osteoprotegerin and low RANKL in primary biliary cirrhosis J Hepatol 38 2003 395 400
26. D. Hegedus, V. Ferencz, P.L. Lakatos, S. Meszaros, P. Lakatos, and C. Horvath Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease J Bone Miner Res 17 2002 1961 1967
27. J.L. Gonzalez-Calvin, J.L. Mundi, F.J. Casado, and E.G. Olivares Bone mineral density and serum levels of estradiol and osteoprotegerin in postmenopausal women with viral cirrhosis Gastroenterology 126 2004 1225 1226
28. H.L. Bonkovsky, M. Hawkins, K. Steinberg, T. Hersh, J.T. Galambos, and J.M. Henderson Prevalence and prediction of osteopenia in chronic liver disease Hepatology 12 1990 273 280
29. L.E. Theill, W.J. Boyle, and J.M. Penninger RANK-L and RANK: T cells, bone loss, and mammalian evolution Annu Rev Immunol 20 2002 795 823
30. G. Schett, S. Kiechl, K. Redlich, F. Oberhollenzer, S. Weger, and G. Egger Soluble RANKL and risk of nontraumatic fracture J Am Med Assoc 291 2004 1108 1113
31. J. Lam, F.P. Ross, and S.L. Teitelbaum RANK ligand stimulates anabolic bone formation J Bone Miner Res 16 2001 S150
32. H. Melhus Soluble RANKL and risk of nontraumatic fracture J Am Med Assoc 291 2004 2703 2704
33. E.C. Buxton, W. Yao, and N.E. Lane Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34) J Clin Endocrinol Metab 89 2004 3332 3336
34. M. Ziolkowska, M. Kurowska, A. Radzikowska, G. Luszczykiewicz, P. Wiland, and W. Dziewczopolski High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment Arthritis Rheum 46 2002 1744 1753
35. L.C. Hofbauer, and M. Schoppet Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases J Am Med Assoc 292 2004 490 495
36. K. Yano, E. Tsuda, N. Washida, F. Kobayashi, M. Goto, and A. Harada Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis J Bone Miner Res 14 1999 518 527
37. A. Fahrleitner-Pammer, H. Dobnig, C. Piswanger-Soelkner, C. Bonelli, H.P. Dimai, and G. Leb Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status Wien Klin Wochenschr 115 2003 291 297
38. S. Colucci, G. Brunetti, R. Rizzi, A. Zonno, G. Mori, and G. Colaianni T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction Blood 104 2004 3722 3730
39. K. Fuller, C. Murphy, B. Kirstein, S.W. Fox, and T.J. Chambers TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL Endocrinology 143 2002 1108 1118
40. W.J. Boyle, W.S. Simonet, and D.L. Lacey Osteoclast differentiation and activation Nature 423 2003 337 342
41. L.C. Hofbauer, D.L. Lacey, C.R. Dunstan, T.C. Spelsberg, B.L. Riggs, and S. Khosla Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells Bone 25 1999 255 259
42. M.D. Wheeler, H. Kono, M. Yin, M. Nakagami, T. Uesugi, and G.E. Arteel The role of Kupffer cell oxidant production in early ethanol-induced liver disease Free Radic Biol Med 31 2001 1544 1549
43. A. Canbay, A.E. Feldstein, H. Higuchi, N. Werneburg, A. Grambihler, and S.F. Bronk Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression Hepatology 38 2003 1188 1198
44. S. Kudlacek, B. Schneider, W. Woloszczuk, P. Pietschmann, and R. Willvonseder Serum levels of osteoprotegerin increase with age in a healthy adult population Bone 32 2003 681 686
45. C.N. Bernstein, M. Sargent, and W.D. Leslie Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study Inflamm Bowel Dis 11 2005 325 330
46. R.N. Pugh, I.M. Murray-Lyon, J.L. Dawson, M.C. Pietroni, and R. Williams Transection of the oesophagus for bleeding oesophageal varices Br J Surg 60 1973 646 649